JP2012500020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012500020A5 JP2012500020A5 JP2011523807A JP2011523807A JP2012500020A5 JP 2012500020 A5 JP2012500020 A5 JP 2012500020A5 JP 2011523807 A JP2011523807 A JP 2011523807A JP 2011523807 A JP2011523807 A JP 2011523807A JP 2012500020 A5 JP2012500020 A5 JP 2012500020A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- acid substitutions
- germline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 83
- 238000006467 substitution reaction Methods 0.000 claims 48
- 210000004602 germ cell Anatomy 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 101000777599 Homo sapiens C-C chemokine receptor type 2 Proteins 0.000 claims 12
- 102000043994 human CCR2 Human genes 0.000 claims 12
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000004044 response Effects 0.000 claims 5
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 4
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000001616 monocyte Anatomy 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 claims 1
- 102000012422 Collagen Type I Human genes 0.000 claims 1
- 108010022452 Collagen Type I Proteins 0.000 claims 1
- 206010061788 Corneal infection Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000001275 ca(2+)-mobilization Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000048160 human CCR5 Human genes 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 102200069457 rs35211634 Human genes 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18935708P | 2008-08-18 | 2008-08-18 | |
| US61/189,357 | 2008-08-18 | ||
| PCT/US2009/004711 WO2010021697A2 (en) | 2008-08-18 | 2009-08-17 | Antibodies to ccr2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012500020A JP2012500020A (ja) | 2012-01-05 |
| JP2012500020A5 true JP2012500020A5 (OSRAM) | 2013-08-29 |
| JP5685535B2 JP5685535B2 (ja) | 2015-03-18 |
Family
ID=41347729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523807A Active JP5685535B2 (ja) | 2008-08-18 | 2009-08-17 | Ｃｃｒ２に対する抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8710191B2 (OSRAM) |
| EP (1) | EP2321351B1 (OSRAM) |
| JP (1) | JP5685535B2 (OSRAM) |
| KR (1) | KR101772706B1 (OSRAM) |
| CN (1) | CN102239180B (OSRAM) |
| AU (1) | AU2009283199B2 (OSRAM) |
| BR (1) | BRPI0916973A2 (OSRAM) |
| CA (1) | CA2734578C (OSRAM) |
| CO (1) | CO6351802A2 (OSRAM) |
| DK (1) | DK2321351T3 (OSRAM) |
| ES (1) | ES2658117T3 (OSRAM) |
| IL (1) | IL211284A (OSRAM) |
| MX (1) | MX2011001911A (OSRAM) |
| MY (1) | MY160892A (OSRAM) |
| NO (1) | NO2321351T3 (OSRAM) |
| NZ (1) | NZ591471A (OSRAM) |
| PE (1) | PE20110774A1 (OSRAM) |
| RU (1) | RU2547595C2 (OSRAM) |
| SG (2) | SG193216A1 (OSRAM) |
| WO (1) | WO2010021697A2 (OSRAM) |
| ZA (1) | ZA201101047B (OSRAM) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011116299A2 (en) * | 2010-03-18 | 2011-09-22 | Colorado State University Research Foundation | Myeloid derived suppressor cell inhibiting agents |
| US20110038871A1 (en) * | 2009-08-11 | 2011-02-17 | Veena Viswanth | Ccr2 inhibitors for treating conditions of the eye |
| ES2721378T3 (es) * | 2011-01-10 | 2019-07-31 | Novimmune Sa | Anticuerpos anti-TLR4 y métodos de uso de los mismos |
| CN102603649B (zh) * | 2011-01-20 | 2016-05-25 | 赣南师范学院 | 一种以地巴唑为先导分子的荧光探针化合物及其制备方法 |
| US20120288442A1 (en) * | 2011-05-11 | 2012-11-15 | Atomic Energy Council-Institute Of Nuclear Energy Research | Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis |
| WO2012172337A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating cardiovascular disease |
| WO2012172346A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating respiratory conditions |
| CN103796693B (zh) | 2011-06-13 | 2017-05-31 | Ith免疫治疗控股股份公司 | 治疗与代谢综合征相关的病症 |
| US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
| WO2012172343A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating primary sclerosing cholangitis |
| ES2664836T3 (es) | 2011-06-13 | 2018-04-23 | Tla Targeted Immunotherapies Ab | Tratamiento de esclerosis múltiple |
| DK2718312T3 (en) | 2011-06-13 | 2018-10-15 | Tla Targeted Immunotherapies Ab | TREATMENT OF CONDITIONS CONNECTED WITH SEPSIS |
| WO2012172336A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory skin diseases |
| WO2012172339A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating inflammatory arthritis |
| US20140349321A1 (en) * | 2011-12-16 | 2014-11-27 | Agency For Science, Technology And Research | Binding molecules against dengue virus and uses thereof |
| HK1208236A1 (en) | 2012-06-22 | 2016-02-26 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
| US8975290B2 (en) | 2013-03-01 | 2015-03-10 | Colorado State University Research Foundation | Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis |
| CA2902026C (en) * | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US10527634B2 (en) | 2015-02-26 | 2020-01-07 | Adventdx | Diagnostic markers of cognitive impairments, kits and uses thereof |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| US10752679B2 (en) | 2016-05-02 | 2020-08-25 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3452508A1 (en) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| SG10202012080UA (en) | 2016-06-03 | 2021-01-28 | Chemocentryx Inc | Method of treating liver fibrosis |
| KR102754341B1 (ko) | 2016-11-23 | 2025-01-13 | 케모센트릭스, 인크. | 국소 분절 사구체경화증의 치료 방법 |
| WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CN110709422B (zh) | 2017-04-19 | 2023-12-26 | 马伦戈治疗公司 | 多特异性分子及其用途 |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| MX2019013045A (es) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| EP3694504A4 (en) | 2017-10-11 | 2021-07-14 | ChemoCentryx, Inc. | TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CRC2 ANTAGONISTS |
| WO2019078344A1 (ja) | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| JP7348899B2 (ja) | 2017-12-08 | 2023-09-21 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性分子及びその使用 |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| US11746150B2 (en) | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| AU2019299217B2 (en) | 2018-07-03 | 2025-04-03 | Fennec Pharmaceuticals, Inc. | Formulations of anhydrous sodium thiosulfate |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| EP3856350A1 (en) | 2018-09-27 | 2021-08-04 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| EP3891181A4 (en) * | 2018-12-04 | 2022-08-17 | Novartis AG | BINDING MOLECULES AGAINST CD3 AND USES THEREOF |
| BR112021012338A2 (pt) | 2018-12-24 | 2021-09-14 | Sanofi | Proteínas de ligação multiespecíficas com domínios fab mutantes |
| US20220146534A1 (en) * | 2019-01-16 | 2022-05-12 | Yeda Research And Development, Co., Ltd. | Biomarkers for CNS Disease Modification |
| AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
| AU2020259884A1 (en) * | 2019-04-17 | 2021-10-07 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
| WO2020232127A1 (en) | 2019-05-13 | 2020-11-19 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind ccr2 to modulate cellular function |
| AU2020303586A1 (en) * | 2019-06-26 | 2022-01-20 | Amunix Pharmaceuticals, Inc. | EGFR antigen binding fragments and compositions comprising same |
| US11707610B2 (en) | 2019-12-13 | 2023-07-25 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| US12319958B2 (en) * | 2020-07-21 | 2025-06-03 | Rutgers, The State University Of New Jersey | Method and kit for CCR2 expression profiling and disease stratification |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| MX2024004447A (es) | 2021-10-27 | 2024-05-08 | Granite Bio Ag | Anticuerpos dirigidos a ccr2. |
| CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
| WO2024245988A1 (en) | 2023-05-29 | 2024-12-05 | Granite Bio Ag | Antibodies targeting ccr2 |
| CN116510020A (zh) * | 2023-06-01 | 2023-08-01 | 中国人民解放军军事科学院军事医学研究院 | 降低ccr2含量或活性的物质在治疗或预防发热伴血小板减少综合征中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU664976B2 (en) | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| EP0619738B1 (en) | 1991-12-02 | 2003-07-09 | Millennium Pharmaceuticals, Inc. | Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| AU705616B2 (en) | 1995-04-21 | 1999-05-27 | Cell Genesys, Inc. | Generation of large genomic DNA deletions |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| SE9600820D0 (sv) | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO1999045031A2 (en) | 1998-03-03 | 1999-09-10 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US6727349B1 (en) * | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
| US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| SI2112166T1 (sl) | 1998-12-23 | 2019-05-31 | Pfizer Inc. | Človeška monoklonska protitelesa proti CTLA-4 |
| CA2399080C (en) | 2000-02-03 | 2013-05-21 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
| US20030165988A1 (en) * | 2002-02-08 | 2003-09-04 | Shaobing Hua | High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins |
| DK1461300T3 (da) | 2001-11-30 | 2011-10-24 | Biogen Idec Inc | Antistoffer mod kemotaktiske monocytproteiner |
| WO2003066830A2 (en) | 2002-02-08 | 2003-08-14 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
| UA87979C2 (ru) | 2002-08-19 | 2009-09-10 | Астразенека Аб | Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1) |
| CN1681926A (zh) | 2002-09-12 | 2005-10-12 | 财团法人化学及血清疗法研究所 | 人的抗人mcp－1抗体和该抗体的片段 |
| EP2135619A1 (en) | 2003-12-10 | 2009-12-23 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| EA010350B1 (ru) | 2004-06-03 | 2008-08-29 | Новиммун С.А. | Антитела против cd3 и способы их применения |
| WO2006085961A2 (en) | 2004-06-30 | 2006-08-17 | Centocor, Inc. | Anti-mcp-1 antibodies, compositions, methods and uses |
| EP1778285A2 (en) | 2004-07-30 | 2007-05-02 | Pfizer Products Inc. | Treatment of ccr2 mediated diseases or disorders |
| MX2009003762A (es) | 2006-10-05 | 2009-07-10 | Centocor Ortho Biotech Inc | Antagonistas del receptor cc-quimiocina 2 para el tratamiento de fibrosis. |
-
2009
- 2009-08-17 NO NO09789161A patent/NO2321351T3/no unknown
- 2009-08-17 MY MYPI2011000512A patent/MY160892A/en unknown
- 2009-08-17 WO PCT/US2009/004711 patent/WO2010021697A2/en not_active Ceased
- 2009-08-17 CA CA2734578A patent/CA2734578C/en active Active
- 2009-08-17 KR KR1020117006355A patent/KR101772706B1/ko not_active Expired - Fee Related
- 2009-08-17 BR BRPI0916973A patent/BRPI0916973A2/pt not_active IP Right Cessation
- 2009-08-17 SG SG2013063318A patent/SG193216A1/en unknown
- 2009-08-17 CN CN200980136307.1A patent/CN102239180B/zh not_active Expired - Fee Related
- 2009-08-17 US US13/059,702 patent/US8710191B2/en active Active
- 2009-08-17 EP EP09789161.8A patent/EP2321351B1/en active Active
- 2009-08-17 JP JP2011523807A patent/JP5685535B2/ja active Active
- 2009-08-17 ES ES09789161.8T patent/ES2658117T3/es active Active
- 2009-08-17 AU AU2009283199A patent/AU2009283199B2/en not_active Ceased
- 2009-08-17 DK DK09789161.8T patent/DK2321351T3/en active
- 2009-08-17 NZ NZ591471A patent/NZ591471A/xx unknown
- 2009-08-17 RU RU2011110169/10A patent/RU2547595C2/ru active
- 2009-08-17 PE PE2011000160A patent/PE20110774A1/es active IP Right Grant
- 2009-08-17 MX MX2011001911A patent/MX2011001911A/es active IP Right Grant
- 2009-08-17 SG SG10201701323TA patent/SG10201701323TA/en unknown
-
2011
- 2011-02-09 ZA ZA2011/01047A patent/ZA201101047B/en unknown
- 2011-02-17 IL IL211284A patent/IL211284A/en active IP Right Grant
- 2011-03-11 CO CO11030038A patent/CO6351802A2/es active IP Right Grant
-
2014
- 2014-04-03 US US14/244,167 patent/US9238691B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500020A5 (OSRAM) | ||
| RU2011110169A (ru) | Антитела против ccr2 | |
| US11981733B2 (en) | LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof | |
| JP2012525829A5 (OSRAM) | ||
| RU2009128064A (ru) | Антитела к cd44 | |
| JP2012530496A5 (OSRAM) | ||
| JP2012501669A5 (OSRAM) | ||
| JP2011509245A5 (OSRAM) | ||
| JP2010511388A5 (OSRAM) | ||
| CN109311971A (zh) | 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途 | |
| JP2012501670A5 (OSRAM) | ||
| JP2010538608A5 (OSRAM) | ||
| JP2010526028A5 (OSRAM) | ||
| JP2018510617A5 (OSRAM) | ||
| TW202019969A (zh) | Ｓｔ２ｌ拮抗劑及使用方法 | |
| JP2019522961A5 (OSRAM) | ||
| JP2020519562A (ja) | 抗インターフェロンガンマ抗体およびその使用法 | |
| CN114685657A (zh) | 一种功能增强型抗体阻断剂的开发及其应用 | |
| RU2011143903A (ru) | Антитела к человеческому tweak и их применение | |
| JP2013519690A5 (OSRAM) | ||
| CN111247173A (zh) | 抗msln抗体及包含其的用于癌症治疗的药物组合物 | |
| JP2017529324A5 (OSRAM) | ||
| RU2019123112A (ru) | Анти-il-5 антитела | |
| CN114573702A (zh) | 一种新型肿瘤衔接器治疗药物的开发和应用 | |
| JP2015518368A5 (OSRAM) |